Pivotal Phase III Success for RGX-202 in Duchenne Muscular Dystrophy, REGENXBIO Targets 2027 Launch
RGNX sits 36% above its 52-week low of $7.35 on elevated volume (2.2× avg).
Summary
REGENXBIO announced highly positive topline results from its pivotal Phase III AFFINITY Duchenne® study of RGX-202, achieving the primary endpoint with 93% of patients demonstrating microdystrophin expression. The study also showed a significant correlation between microdystrophin expression and functional improvement, alongside a well-tolerated safety profile. This critical success provides a much-needed positive catalyst for REGENXBIO, which has recently faced substantial doubt about its ability to continue as a going concern and experienced critical FDA setbacks for other gene therapies like RGX-121 and RGX-111. The positive Phase III data for RGX-202 could fundamentally alter the company's financial trajectory and investment thesis, offering a clear path to potential accelerated approval and commercial launch in 2027. Traders will now closely monitor regulatory submissions and the company's progress towards bringing this therapy to market.
At the time of this announcement, RGNX was trading at $10.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $518.2M. The 52-week trading range was $7.35 to $16.19. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.